Genetic Causes
The primary cause of this condition is a mutation in the TTR gene, which instructs the liver to produce a protein called transthyretin. In healthy individuals, this protein transports vitamin A and thyroid hormones, but the mutation causes the protein to become unstable and misfold. These misfolded proteins clump together to form amyloid fibrils, which circulate in the bloodstream and deposit into nerves, the heart, and other tissues, disrupting their normal function.

Inheritance and Risk Factors
This disease is inherited in an autosomal dominant pattern, meaning a child only needs to inherit the mutated gene from one parent to be at risk. The most significant risk factor is a family history of the disease. However, not everyone who carries the mutation will develop symptoms, a concept known as variable penetrance. Ethnicity can also play a role, as certain mutations are more common in specific populations, such as those of Portuguese, Swedish, Japanese, or African descent.

Prevention
There is currently no way to prevent the genetic mutation that causes the disease or to prevent the onset of symptoms through lifestyle changes if one carries the gene. Primary prevention strategies focus on genetic counseling and family planning for individuals who know they carry the mutation. Once diagnosed, "prevention" shifts to preventing the rapid progression of the disease through early medical intervention.

Signs and Symptoms
Symptoms often begin with sensory issues in the feet, such as numbness, tingling, or burning pain, which progressively spread up the legs and eventually to the hands. Motor symptoms include muscle weakness, wasting, and difficulty walking. Autonomic neuropathy is also common and clinically meaningful, manifesting as severe digestive issues (diarrhea or constipation), dizziness upon standing (orthostatic hypotension), and urinary or sexual dysfunction. Unexplained weight loss and carpal tunnel syndrome often precede other symptoms by years.

Diagnostic Tests
Clinicians identify the condition through a combination of physical exams and specific tests. Genetic testing is the gold standard to confirm the presence of a TTR gene mutation. Tissue biopsies (often of fat, nerve, or salivary gland) stained with Congo red dye are used to visualize amyloid deposits. Additional tests may include nerve conduction studies to assess the extent of neuropathy and cardiac imaging (such as echocardiograms or scintigraphy) to check for heart involvement.

Differential Diagnosis
Because the symptoms mimic other more common nerve disorders, the condition is frequently misdiagnosed. It is often confused with chronic inflammatory demyelinating polyneuropathy (CIDP), diabetic neuropathy, or idiopathic axonal polyneuropathy. The presence of autonomic symptoms and a family history are key clues that help distinguish it from these other conditions.

Disease-Modifying Medications
Modern treatment focuses on reducing the production of the abnormal protein or stabilizing it to prevent deposits. TTR silencers are medications that use RNA interference or antisense technology to stop the liver from making the transthyretin protein. TTR stabilizers bind to the protein to keep it from falling apart and forming amyloid fibrils. These treatments address the underlying cause and are most effective when started early to slow or halt progression.

Symptom Management
Supportive care is crucial for maintaining quality of life. Neuropathic pain is often managed with specific anti-seizure medications or antidepressants known to help nerve pain. Autonomic symptoms require targeted management; for example, wearing compression stockings and increasing salt intake for low blood pressure, or using specific medications to regulate bowel movements. Physical and occupational therapy help maintain mobility and function.

Procedures and Monitoring
In some cases, a liver transplant may be performed, particularly for certain mutations, as the new liver will produce normal transthyretin. However, this is less common now due to the availability of effective drug therapies. Regular monitoring includes cardiac, renal, and neurological assessments to track disease progression and adjust treatments.

When to Seek Medical Care
Patients should see a doctor immediately if they experience sudden fainting, severe chest pain, or rapid irregular heartbeats. Routine follow-up is needed if numbness spreads, weakness increases, or if gastrointestinal symptoms become unmanageable. Early reporting of new symptoms helps the care team adjust therapies before permanent damage occurs.

Severity and Disease Course
Polyneuropathy of hereditary transthyretin-mediated amyloidosis is a severe condition that varies from mild sensory changes in the early stages to profound disability in later stages. The disease is progressive, typically moving through stages: from independent walking with sensory symptoms, to requiring assistance like a cane or walker, and eventually to being wheelchair-bound or bedridden. The rate of progression depends heavily on the specific genetic mutation and the age of onset.

Prognosis and Life Expectancy
Without treatment, the prognosis is poor, with a historical life expectancy of 7 to 10 years after symptom onset, often due to heart failure or wasting. However, the introduction of genetic therapies has fundamentally changed this outlook, allowing many patients to live much longer and maintain higher function. Early diagnosis is the most critical factor influencing prognosis, as treatment can preserve nerve function but generally cannot reverse damage that has already occurred.

Complications
Long-term complications include severe muscle atrophy, loss of bladder and bowel control, and cardiac amyloidosis, where amyloid deposits stiffen the heart muscle. Kidney dysfunction and vision problems (such as glaucoma or vitreous opacities) can also develop over time. These systemic effects make the condition a multi-organ disease requiring comprehensive care.

Impact on Activities and Mobility
As nerve damage progresses, daily tasks requiring fine motor skills (like buttoning a shirt) or walking long distances become difficult. Patients often need to adapt their homes with safety bars and use mobility aids. Driving may become unsafe if sensation in the feet is lost. Fatigue and autonomic issues can severely limit the ability to work full-time or participate in social events.

Diet and Coping
Digestive issues are a major daily challenge; patients may need to eat small, frequent meals and avoid foods that trigger gastrointestinal distress. Managing orthostatic hypotension may require lifestyle changes like rising slowly from a seated position and staying hydrated. Mental health support is vital, as coping with a progressive genetic condition can lead to anxiety and depression.

Questions to Ask Your Healthcare Provider

• What specific genetic mutation do I have, and how does it typically progress?
• Am I a candidate for TTR silencer or stabilizer medications?
• How often should I have my heart and eyes checked for amyloid deposits?
• What can I do to manage the digestive and blood pressure symptoms at home?
• Should my children or siblings undergo genetic testing?
• Are there any clinical trials or patient registries I should join?

Q: Is polyneuropathy of hereditary transthyretin-mediated amyloidosis curable?
A: Currently, there is no absolute cure that removes existing amyloid deposits completely, but treatments can stop the disease from getting worse and significantly improve quality of life. In rare cases, liver transplant has been considered a curative approach for the genetic source of the protein, but it does not remove existing deposits.

Q: How is this different from other types of amyloidosis?
A: This type is genetic and caused by a mutation in the TTR gene. Other types, like wild-type ATTR (age-related) or AL amyloidosis (related to blood cell abnormalities), have different causes, treatments, and progression rates.

Q: If I have the gene, will I definitely get the disease?
A: Not necessarily. This is known as incomplete penetrance. Some people carry the mutation and live into old age without ever developing symptoms, although the reasons for this are not fully understood.

Q: Can diet or exercise prevent the amyloid buildup?
A: No specific diet or exercise regimen can prevent the production of the abnormal protein or the formation of amyloid deposits. However, a healthy lifestyle helps the body cope better with the symptoms and complications.

Q: Is the condition contagious?
A: No, it is a genetic disorder inherited from parents and cannot be caught from or transmitted to another person through contact.